UK Markets closed

Cyteir Therapeutics, Inc. (CYT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.9200+0.0300 (+1.59%)
At close: 04:00PM EDT
1.9200 0.00 (0.00%)
After hours: 04:49PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 319.5000
52-week low 31.5550
50-day moving average 32.3230
200-day moving average 34.0251

Share statistics

Avg vol (3-month) 350.93k
Avg vol (10-day) 327.28k
Shares outstanding 535.37M
Implied shares outstanding 6N/A
Float 811.28M
% held by insiders 111.56%
% held by institutions 179.37%
Shares short (14 Jul 2022) 4460.46k
Short ratio (14 Jul 2022) 42.31
Short % of float (14 Jul 2022) 42.39%
Short % of shares outstanding (14 Jul 2022) 41.30%
Shares short (prior month 14 Jun 2022) 4846.29k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-22.40%
Return on equity (ttm)-38.06%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -48.52M
Net income avi to common (ttm)-48.92M
Diluted EPS (ttm)-3.2040
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)177.38M
Total cash per share (mrq)5.03
Total debt (mrq)3.02M
Total debt/equity (mrq)1.73
Current ratio (mrq)19.77
Book value per share (mrq)5.64

Cash flow statement

Operating cash flow (ttm)-41.83M
Levered free cash flow (ttm)-25.5M